{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:39:00Z","timestamp":1790998740785,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07692-1","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:04:14Z","timestamp":1751555054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Physicochemical characterization and biological evaluation of amorphous solid dispersions of an anticancerous drug: Erlotinib HCl"],"prefix":"10.1038","volume":"15","author":[{"given":"K. P.","family":"Safna Hussan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thekkekara D.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Shahin","family":"Thayyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Sreeshma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Archana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"7692_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","volume":"420","author":"Y Kawabata","year":"2011","unstructured":"Kawabata, Y., Wada, K., Nakatani, M., Yamada, S. & Onoue, S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 420, 1\u201310. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.08.032 (2011).","journal-title":"Int. J. Pharm."},{"key":"7692_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188319","volume":"1873","author":"UH Gala","year":"2020","unstructured":"Gala, U. H., Miller, D. A. & Williams, R. O. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim. Biophys. Acta - Rev. Cancer 1873, 188319. https:\/\/doi.org\/10.1016\/j.bbcan.2019.188319 (2020).","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"7692_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1107\/S1600536808011707","volume":"6","author":"S Selvanayagam","year":"2008","unstructured":"Selvanayagam, S., Sridhar, B. & Ravikumar, K. Erlotinib hydro-chloride: An anti-cancer agent. Acta Crystallogr. Sect. E Struct. Rep. Online 6, 4. https:\/\/doi.org\/10.1107\/S1600536808011707 (2008).","journal-title":"Acta Crystallogr. Sect. E Struct. Rep. Online"},{"key":"7692_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5012\/bkcs.2011.32.3.909","volume":"32","author":"D Asgari","year":"2011","unstructured":"Asgari, D., Aghanejad, A. & Mojarrad, J. S. An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate. Bull. Korean Chem. Soc. 32, 909\u2013914. https:\/\/doi.org\/10.5012\/bkcs.2011.32.3.909 (2011).","journal-title":"Bull. Korean Chem. Soc."},{"key":"7692_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5681\/apb.2012.017","volume":"2","author":"L Barghi","year":"2012","unstructured":"Barghi, L., Aghanejad, A., Valizadeh, H., Barar, J. & Asgari, D. Modified synthesis of erlotinib hydrochloride. Adv. Pharm. Bull. 2, 119\u2013122. https:\/\/doi.org\/10.5681\/apb.2012.017 (2012).","journal-title":"Adv. Pharm. Bull."},{"key":"7692_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/biomethods\/bpac001","volume":"7","author":"A Jahangiri","year":"2022","unstructured":"Jahangiri, A., Khalilzad, F. & Barghi, L. Dissolution improvement of binary solid dispersions of erlotinib prepared by one-step electrospray method. Biol. Methods Protoc. 7, 1\u20135. https:\/\/doi.org\/10.1093\/biomethods\/bpac001 (2022).","journal-title":"Biol. Methods Protoc."},{"issue":"2","key":"7692_CR7","first-page":"1","volume":"O2","author":"RL Dumpala","year":"2020","unstructured":"Dumpala, R. L., Patadiya, N., Patil, C. & Universiy, P. Solubility and dissolution enhancement of erlotinib by liquisolid compact technique. Pharma O2(2), 1\u201310 (2020).","journal-title":"Pharma"},{"key":"7692_CR8","doi-asserted-by":"publisher","first-page":"121852","DOI":"10.1016\/j.ijpharm.2022.121852","volume":"622","author":"S Jain","year":"2022","unstructured":"Jain, S. et al. Enhanced stability and oral bioavailability of erlotinib by solid self nano emulsifying drug delivery systems. Int. J. Pharm. 622, 121852 (2022).","journal-title":"Int. J. Pharm."},{"key":"7692_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2015.10.080","author":"CP Dora","year":"2015","unstructured":"Dora, C. P. et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, invitro cytotoxicity and oral bioavailability. Carbohydr. Polym. https:\/\/doi.org\/10.1016\/j.carbpol.2015.10.080 (2015).","journal-title":"Carbohydr. Polym."},{"key":"7692_CR10","doi-asserted-by":"crossref","unstructured":"C. Parimala Devi, Ganthala a b, S. Alavala, N. Chella, S.B. Andugulapati, N.B. Bathini, R. Sistl, Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K\/AKT inhibition. Colloids Surfaces B Biointerfaces 211 (2022).","DOI":"10.1016\/j.colsurfb.2021.112305"},{"key":"7692_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030996","author":"G Chauhan","year":"2023","unstructured":"Chauhan, G., Wang, X., Yousry, C. & Gupta, V. Scalable production and in vitro efficacy of inhaled Erlotinib Nanoemulsion for enhanced efficacy in non-small cell lung cancer (NSCLC). Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics15030996 (2023).","journal-title":"Pharmaceutics"},{"key":"7692_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/10837450.2023.2233612","volume":"28","author":"L Mugnier","year":"2023","unstructured":"Mugnier, L., Espitalier, F., Menegotto, J., Bell, S. & R\u00e9, M. I. Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer. Pharm. Dev. Technol. 28, 697\u2013707. https:\/\/doi.org\/10.1080\/10837450.2023.2233612 (2023).","journal-title":"Pharm. Dev. Technol."},{"key":"7692_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.11.015","volume-title":"Polyethylene glycols in oral and parenteral formulations\u2014A critical review","author":"RP Gullapalli","year":"2015","unstructured":"Gullapalli, R. P. & Mazzitelli, C. L. Polyethylene glycols in oral and parenteral formulations\u2014A critical review (Elsevier, 2015). https:\/\/doi.org\/10.1016\/j.ijpharm.2015.11.015."},{"key":"7692_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/03602559.2014.979506","volume":"37","author":"P Taylor","year":"2015","unstructured":"Taylor, P., Teodorescu, M. & Bercea, M. Poly (vinylpyrrolidone)\u2014A versatile polymer for biomedical and beyond medical applications. Polymer Plast. Technol. Eng. 37, 41. https:\/\/doi.org\/10.1080\/03602559.2014.979506 (2015).","journal-title":"Polymer Plast. Technol. Eng."},{"key":"7692_CR15","doi-asserted-by":"publisher","first-page":"S1138","DOI":"10.1016\/j.arabjc.2013.02.006","volume":"10","author":"ST Latha","year":"2017","unstructured":"Latha, S. T. et al. Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation. Arab. J. Chem. 10, S1138\u2013S1144. https:\/\/doi.org\/10.1016\/j.arabjc.2013.02.006 (2017).","journal-title":"Arab. J. Chem."},{"key":"7692_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113631","volume":"192","author":"XY Teoh","year":"2021","unstructured":"Teoh, X. Y., Goh, C. F., Aminu, N. & Chan, S. Y. Quantification of atovaquone from amorphous solid dispersion formulation using HPLC: An in vitro and ex vivo investigation. J. Pharm. Biomed. Anal. 192, 113631. https:\/\/doi.org\/10.1016\/j.jpba.2020.113631 (2021).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"7692_CR17","doi-asserted-by":"publisher","first-page":"120072","DOI":"10.1016\/j.molliq.2022.120072","volume":"365","author":"KP Safna Hussan","year":"2022","unstructured":"Safna Hussan, K. P., Shahin Thayyil, M., Pareeth, C. M., Manoj, K. & Babu, T. D. Molecular dynamics in amorphous double active ionic liquid developed by chemical structural modification of ibuprofen. J. Mol. Liq. 365, 120072. https:\/\/doi.org\/10.1016\/j.molliq.2022.120072 (2022).","journal-title":"J. Mol. Liq."},{"key":"7692_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/10715762.2022.2065990","volume":"56","author":"KP Safna Hussan","year":"2022","unstructured":"Safna Hussan, K. P. et al. Antioxidant activity of erlotinib and gefitinib: Theoretical and experimental insights. Free Radic. Res. 56, 196\u2013208 (2022).","journal-title":"Free Radic. Res."},{"key":"7692_CR19","unstructured":"R. Tirumalai, <71> Sterility Test, (n.d.). https:\/\/www.usp.org\/harmonization-standards\/pdg\/general-methods\/sterility-test."},{"key":"7692_CR20","unstructured":"\u232985\u232a Bacterial Endotoxins Test, (n.d.). https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/harmonization\/gen-method\/q06_current_webpage_stage_6_monograph_23_nov_2011.pdf."},{"key":"7692_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2872","author":"S Christopher Jeyaseelan","year":"2021","unstructured":"Christopher Jeyaseelan, S. & Milton Franklin Benial, A. Spectroscopic characterization, DFT studies, molecular docking and cytotoxic evaluation of 4-nitro-indole-3-carboxaldehyde: A potent lung cancer agent. J. Mol. Recognit. https:\/\/doi.org\/10.1002\/jmr.2872 (2021).","journal-title":"J. Mol. Recognit."},{"key":"7692_CR22","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/1535-7163.MCT-06-0514","volume":"6","author":"F Yamasaki","year":"2007","unstructured":"Yamasaki, F. et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol. Cancer Ther. 6, 2168\u20132178. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0514 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"7692_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm87020009","author":"N Nyoman","year":"2019","unstructured":"Nyoman, N., Sutrisni, W., Soewandhi, S. N. & Adnyana, I. K. Acute and subchronic (28-day) oral toxicity studies on the film formulation of k-carrageenan and konjac glucomannan for soft capsule application. Sci. Pharm. https:\/\/doi.org\/10.3390\/scipharm87020009 (2019).","journal-title":"Sci. Pharm."},{"key":"7692_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1254\/jphs.FP0060907","volume":"103","author":"S Natesan","year":"2007","unstructured":"Natesan, S., Badami, S., Dongre, S. H. & Godavarthi, A. Antitumor activity and antioxidant status of the methanol extract of Careya arborea bark against Dalton\u2019s lymphoma ascites-induced ascitic and solid tumor in mice. J. Pharmacol. Sci. 103, 12\u201323. https:\/\/doi.org\/10.1254\/jphs.FP0060907 (2007).","journal-title":"J. Pharmacol. Sci."},{"key":"7692_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s10616-016-0002-2","volume":"68","author":"R Kumar","year":"2016","unstructured":"Kumar, R., Kumar, N., Ramalingayya, G. V., Setty, M. M. & Pai, K. S. R. Evaluation of Ceiba pentandra (L.) Gaertner bark extracts for in vitro cytotoxicity on cancer cells and in vivo antitumor activity in solid and liquid tumor models. Cytotechnology 68, 1909\u20131923. https:\/\/doi.org\/10.1007\/s10616-016-0002-2 (2016).","journal-title":"Cytotechnology"},{"key":"7692_CR26","unstructured":"K. Xiang, M. Xu, Novel crystal of erlotinib base and the preparation method thereof, 2010. https:\/\/patents.google.com\/patent\/US20130137867A1."},{"key":"7692_CR27","unstructured":"K. Xiang, M. Xu, Crystal of erlotinib base and the preparation method thereof, 2014. https:\/\/patents.google.com\/patent\/US8653264B2."},{"key":"7692_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4236\/pp.2018.99030","volume":"9","author":"S Sarker","year":"2018","unstructured":"Sarker, S. et al. Formulation development and in-vivo evaluation of atorvastatin calcium solid dispersion in streptozotocin induced diabetic mice. Pharmacol. Pharm. 9, 395\u2013414 (2018).","journal-title":"Pharmacol. Pharm."},{"key":"7692_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molliq.2015.10.017","volume":"213","author":"I Bahadur","year":"2016","unstructured":"Bahadur, I. et al. Interactions of polyvinylpyrrolidone with imidazolium based ionic liquids: Spectroscopic and Density Functional Theory studies. J. Mol. Liq. 213, 13\u201316. https:\/\/doi.org\/10.1016\/j.molliq.2015.10.017 (2016).","journal-title":"J. Mol. Liq."},{"key":"7692_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09926","volume":"8","author":"S Cheralayikkal","year":"2022","unstructured":"Cheralayikkal, S., Manoj, K. & Hussan, K. P. S. Formulation and evaluation of a smart drug delivery system of 5- fl uorouracil for pH-sensitive chemotherapy. Heliyon 8, e09926. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09926 (2022).","journal-title":"Heliyon"},{"key":"7692_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1208\/s12249-015-0370-5","volume":"17","author":"DH Truong","year":"2016","unstructured":"Truong, D. H. et al. Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib. AAPS PharmSciTech 17, 466\u2013473 (2016).","journal-title":"AAPS PharmSciTech"},{"key":"7692_CR32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1517\/13543784.12.8.1395","volume":"12","author":"P Bonomi","year":"2003","unstructured":"Bonomi, P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin. Investig. Drugs 12, 1395\u20131401 (2003).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"7692_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/19932820.2020.1846862","volume":"1","author":"AV Naik","year":"2021","unstructured":"Naik, A. V., Dessai, S. N. & Sellappan, K. Antitumour activity of Annona muricata L. leaf methanol extracts against Ehrlich Ascites Carcinoma and Dalton\u2019s Lymphoma Ascites mediated tumours in Swiss albino mice. Libyan J. Med. 1, 6. https:\/\/doi.org\/10.1080\/19932820.2020.1846862 (2021).","journal-title":"Libyan J. Med."},{"key":"7692_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2025.142014","author":"KPS Hussan","year":"2025","unstructured":"Hussan, K. P. S. et al. Molecular dynamics and interactions in amorphous solid dispersion of Erlotinib HCl for improved cancer therapy. Mol. Struct. https:\/\/doi.org\/10.1016\/j.molstruc.2025.142014 (2025).","journal-title":"Mol. Struct."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07692-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:04:16Z","timestamp":1751555056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07692-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7692"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07692-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23787"}}